Kullich W, Klein G, Pöllmann G
Rehabilitation Centre for Rheumatic and Cardiovascular Diseases, Saalfelden, Austria.
Postgrad Med J. 1990;66 Suppl 4:S46-8.
Serum pepsinogen I was determined radioimmunologically in 18 patients suffering from lumbar backache syndromes. These patients were then treated with lornoxicam 4 mg twice daily over a period of 2 weeks. No significant increase in the serum pepsinogen I level was found in 17 (94.4%) of cases. Using the serum pepsinogen I as a parameter for the integrity of the gastric mucosa, this suggests good gastric tolerance of lornoxicam.
采用放射免疫法测定了18例患有腰背痛综合征患者的血清胃蛋白酶原I。然后让这些患者服用氯诺昔康，每日两次，每次4mg，持续2周。17例（94.4%）患者的血清胃蛋白酶原I水平未发现显著升高。以血清胃蛋白酶原I作为胃黏膜完整性的参数，这表明氯诺昔康对胃有良好的耐受性。
